Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

carotuximab 2Bevacizumab 2merphos 1Methotrexate 1Leucovorin 1Dactinomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Choriocarcinoma × carotuximab × Clear all
NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Tracon Pharmaceuticals Inc.

Phase 2 Terminated
3 enrolled 11 charts
Gynecologic

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

NCT02396511 2019-06-11

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
2 enrolled 10 charts

Choriocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡